Currently, there are 170.48M common shares owned by the public and among those 128.57M shares have been available to trade.
The company’s stock has a 5-day price change of 1.61% and -31.97% over the past three months. RLAY shares are trading -23.54% year to date (YTD), with the 12-month market performance down to -55.51% lower. It has a 12-month low price of $1.77 and touched a high of $10.72 over the same period. RLAY has an average intraday trading volume of 2.41 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.66%, 4.49%, and -39.04% respectively.
Institutional ownership of Relay Therapeutics Inc (NASDAQ: RLAY) shares accounts for 77.97% of the company’s 170.48M shares outstanding.
It has a market capitalization of $537.04M and a beta (3y monthly) value of 1.65. The earnings-per-share (ttm) stands at -$2.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.49% over the week and 10.90% over the month.
Analysts forecast that Relay Therapeutics Inc (RLAY) will achieve an EPS of -0.49 for the current quarter, -0.5 for the next quarter and -1.96 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.53 while analysts give the company a high EPS estimate of -0.53. Comparatively, EPS for the current quarter was -0.69 a year ago. Earnings per share for the fiscal year are expected to increase by 14.76%, and -1.71% over the next financial year. EPS should grow at an annualized rate of 4.03% over the next five years, compared to -23.05% over the past 5-year period.
Looking at the support for the RLAY, a number of firms have released research notes about the stock. Wells Fargo stated their Equal Weight rating for the stock in a research note on April 17, 2025, with the firm’s price target at $4. Jefferies coverage for the Relay Therapeutics Inc (RLAY) stock in a research note released on September 10, 2024 offered a Buy rating with a price target of $16. Barclays on their part issued Overweight rating on May 10, 2024.
